Loading…
Clene Inc. is projected to rise to $9.01 by 2027, a +44% move from its current price of $6.27. CLNN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $6.09 | $6.27 | $6.45 | +0.02% |
| Jul 14 | $6.02 | $6.27 | $6.53 | +0.05% |
| Jul 15 | $5.97 | $6.27 | $6.60 | +0.07% |
| Jul 16 | $5.93 | $6.28 | $6.65 | +0.10% |
| Jul 17 | $5.89 | $6.28 | $6.69 | +0.12% |
| Jul 18 | $5.85 | $6.28 | $6.74 | +0.15% |
| Jul 19 | $5.82 | $6.28 | $6.78 | +0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.82 | $6.28 | $6.78 | +0.17% |
| Week 2 | $5.65 | $6.29 | $7.01 | +0.35% |
| Week 3 | $5.52 | $6.30 | $7.19 | +0.52% |
| Week 4 | $5.42 | $6.31 | $7.35 | +0.70% |
| Week 5 | $5.34 | $6.32 | $7.50 | +0.88% |
| Week 6 | $5.26 | $6.34 | $7.63 | +1.05% |
| Week 7 | $5.19 | $6.35 | $7.76 | +1.23% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Clene Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company’s lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene Inc.
is headquartered in Salt Lake City, Utah.
Clene Inc. (CLNN) operates in the Consumer Defensive category and is currently priced at $6.34 with a market capitalization of $80.95M and a market rank of 4100. The stock’s price outlook is framed by a yearly forecast that begins with a neutral 2026, then advances to a bullish outlook through 2035 and beyond.
The 2026 forecast shows a min of $3.92, an avg of $6.34, and a max of $9.73, with an ROI of 0% and a Neutral sentiment. From 2027 onward, the model envisions rising averages and meaningful upside, culminating in substantial long-run upside by 2050. The projected path includes 2027 avg $9.84, 2028 avg $11.44, 2029 avg $11.31, 2030 avg $12.87, 2031 avg $13.70, 2032 avg $14.90, 2033 avg $20.39, 2034 avg $22.80, 2035 avg $23.00, 2040 avg $37.32, and 2050 avg $61.25, with corresponding ROIs of 55.4%, 80.6%, 78.5%, 103.2%, 116.2%, 135.1%, 221.8%, 259.9%, 263%, 489.2%, and 866.8% respectively.
A major floor 24.9% below — a decisive break under it would weaken the trend.
The nearest floor, 15.0% below — buyers have tended to step in here.
The nearest ceiling, 6.9% above — a clean break opens room to run.
A major ceiling 29.0% above — clearing it would confirm fresh momentum.
Key CLNN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CLNN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.15 | Buy | $6.18 | Buy |
| MA 10 | $6.15 | Buy | $6.12 | Buy |
| MA 20 | $5.98 | Buy | $6.07 | Buy |
| MA 50 | $6.27 | Buy | $6.08 | Buy |
| MA 100 | $5.94 | Buy | $6.06 | Buy |
| MA 200 | $6.55 | Sell | $5.99 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.62 | Neutral |
| Stoch RSI (14) | 88.59 | Sell |
| CCI (20) | 111.11 | Buy |
| Williams %R (14) | -11.67 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | 8.67 | Buy |
| Bollinger %B (20,2) | 0.85 | Neutral |
| Stochastic %K (14) | 88.33 | Sell |
| TRIX (15) | -0.09 | Sell |
| Awesome (5,34) | 0.11 | Buy |
| Ultimate (7,14,28) | 58.29 | Neutral |
| Momentum (10) | 0.48 | Buy |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 6.20 | Buy |
| ADX (14) | 8.47 | Neutral |
| ATR (14) | 0.14 | Info |
The 30-day technical picture leans bullish with an RSI of 60. The stock trades near its short- and medium-term moving averages, with the SMA50 at $6.27 and the SMA200 at $6.55. Immediate support sits at $5.33 and resistance at $7.14, suggesting a defined trading band.
Over the last 30 days, the price has ranged from $5.02 to $7.99, signaling modest volatility within a tight band compared with the longer-term history.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.92 | $6.27 | $9.09 | 0% | Neutral | |
| $7.14 | $9.01 | $12.05 | +44% | Bullish | |
| $7.90 | $10.27 | $14.28 | +64% | Bullish | |
| $7.80 | $10.39 | $14.90 | +66% | Bullish | |
| $8.37 | $11.40 | $16.76 | +82% | Bullish | |
| $8.66 | $12.03 | $18.08 | +92% | Bullish | |
| $9.21 | $13.03 | $19.98 | +108% | Bullish | |
| $11.49 | $16.53 | $25.80 | +164% | Bullish | |
| $12.69 | $18.58 | $29.47 | +196% | Bullish | |
| $13.07 | $19.42 | $31.29 | +210% | Bullish | |
| $18.35 | $29.31 | $50.34 | +368% | Bullish | |
| $26.80 | $48.47 | $91.36 | +673% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.92 | $6.27 | $7.65 | +0.00% |
| August 2026 | $5.51 | $6.51 | $7.91 | +3.87% |
| September 2026 | $5.39 | $6.41 | $7.88 | -1.51% |
| October 2026 | $5.52 | $6.62 | $8.21 | +3.14% |
| November 2026 | $5.86 | $7.06 | $8.83 | +6.66% |
| December 2026 | $5.96 | $7.21 | $9.09 | +2.21% |
Click any year to see its month-by-month CLNN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, CLNN could reach as high as $9.09, with a base case around $6.27 and support toward $3.92 — roughly 0% from $6.27. Price action looks broadly range-bound.
Expect CLNN to range from $7.14 to $12.05 through 2027. The $9.01 average target implies a +44% move from current prices. That is up +44% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The CLNN price prediction for 2028 points to an average of $10.27 (low $7.90, high $14.28) — a potential gain of +64% on today's $6.27. Momentum favours further upside here.
In 2029, CLNN is projected to trade between $7.80 and $14.90, averaging $10.39 — a potential gain of +66% from today's $6.27. That is up +1% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Clene Inc.'s 2030 outlook centres on $11.40, within a $8.37 to $16.76 range. That is up +10% on the projected 2029 average. That marks a +82% change versus current levels. Momentum favours further upside here.
By 2031, CLNN could reach as high as $18.08, with a base case around $12.03 and support toward $8.66 — roughly +92% from $6.27. Buyers look set to stay in control over this stretch.
Expect CLNN to range from $9.21 to $19.98 through 2032. The $13.03 average target implies a +108% move from current prices. That is up +8% on the projected 2031 average. Momentum favours further upside here.
The CLNN price prediction for 2033 points to an average of $16.53 (low $11.49, high $25.80) — a potential gain of +164% on today's $6.27. Buyers look set to stay in control over this stretch.
In 2034, CLNN is projected to trade between $12.69 and $29.47, averaging $18.58 — a potential gain of +196% from today's $6.27. That is up +12% on the projected 2033 average. Momentum favours further upside here.
Clene Inc.'s 2035 outlook centres on $19.42, within a $13.07 to $31.29 range. That is up +5% on the projected 2034 average. That marks a +210% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, CLNN could reach as high as $50.34, with a base case around $29.31 and support toward $18.35 — roughly +368% from $6.27. Momentum favours further upside here.
Expect CLNN to range from $26.80 to $91.36 through 2050. The $48.47 average target implies a +673% move from current prices. That is up +65% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in CLNN today (≈ 159.489633 CLNN) could be worth
$7,730.98
+$6,730.98 (+673%) by 2050 · US Dollar
Based on the average projected CLNN price of $48.47 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CLNNwould be worth at today's price.
$1,000 invested in CLNN on Jul 10, 2025 (≈ 265.957447 CLNN) would be worth
$1,667.55
+$667.55 (+66.8%) today · 1.67× · US Dollar
Based on a CLNN entry price of $3.76 vs. today's $6.27.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.1 | $1,027.87 | +2.8% |
| 1 month ago | $5.5 | $1,140 | +14.0% |
| 3 months ago | $6.11 | $1,026.19 | +2.6% |
| 6 months ago | $5.18 | $1,210.42 | +21.0% |
| 1 year ago | $3.76 | $1,667.55 | +66.8% |
| All time (5.0y) ago | $271.6 | $23.09 | -97.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CLNN forecast.
Our base-case forecast reaches $13.00 around 2032.
Implied market cap at $13.00: $166.12M
The multi-year forecast shows a clear bullish trajectory beyond 2026, with rising averages and strong upside potential. By 2030 the avg is projected at $12.87 with a 103.2% ROI, and by 2040 the avg climbs to $37.32 with a 489.2% ROI, indicating substantial long-term appreciation under the scenarios modeled. By 2050 the avg is $61.25 with an 866.8% ROI, underscoring a continued, pronounced upside if the forecast materializes.
These figures are estimates and not guarantees, and actual results will depend on a range of factors including market conditions and company developments. Overall, sentiment remains bullish in the later forecast years, with notable upside in the 2030s and beyond, tempered by the uncertainty inherent to early-stage and small-cap biotech equities.
Tap a question to reveal the answer.
In 2030 the forecast lists min $9.06, avg $12.87, max $19.83 with ROI 103.2% and sentiment bullish.
The forecast shows bullish sentiment from 2027 onward, with rising averages and positive ROIs (e.g., 2027 ROI 55.4%, 2030 ROI 103.2%, 2040 ROI 489.2%, 2050 ROI 866.8%). The 2026 view is Neutral with an avg price of $6.34 and ROI of 0%.
The 2040 forecast shows an avg price of $37.32 and a max of $68.77, with a 489.2% ROI. While the avg is below $50, the max price exceeds $50, suggesting the possibility exists under the modeled scenario.
Current price is $6.34 and market cap is $80.95M.
The 30-day range is $5.02 to $7.99.
Clene Inc. Community Discussion
0Share your Clene Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.